Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH32367 in HER2-Positive Locally Advanced or Metastatic Solid Tumors
NCT05523947Phase 2Recruiting
- Sponsor
- Yuhan
- Start
- Aug 2022
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of ABL105 in solid tumor and biliary tract cancer (BTC), sponsored by Yuhan. Primary endpoints: Treatment-emergent adverse events at 2.5 years and Objective Response Rate at 3.5 years. Started Aug 2022; status: recruiting.
02
Drugs
ABL105
03
Conditions
solid tumorbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05523947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523947.